Live Breaking News & Updates on குழு மீடியா தொடர்பு
Stay updated with breaking news from குழு மீடியா தொடர்பு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Moving Mountains for Multiple Myeloma Program to Hike Through Alaska's Kenai Peninsula-Glaciers, Coastline & Wildlife in August prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
BridgeBio Pharma's Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Pivotal study demonstrated a clinically meaningful rate of tumor shrinkage (overall response rate) and duration of response in patients with previously-treated advanced cholangiocarcinoma (CCA) harboring ....
Helsinn appoints Mary Lynne Hedley to Board of Directors April 29, 2021 03:00 ET | Source: Helsinn Healthcare S.A. Helsinn Healthcare S.A. 20 21 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to announce the appointment of Dr. Mary Lynne Hedley as a new member of its Board of Directors, effective April 28, 2021. Dr. Hedley is an immunologist and cancer cell biologist, with a vast level of experience within the pharmaceutical industry, specifically within the field of oncology. Most recently, Dr Hedley was Director, President and Chief Operating Officer at TESARO, a biotechnology company she co-founded in 2010, focused on the development and global commercialization of oncology therapeutics. During her time at TESARO the team built up a pipeline of early and late stage drug candidates including the commercial product niraparib, a PARP inhibitor that chan ....
Helsinn Healthcare S.A.: Helsinn appoints Mary Lynne Hedley to Board of Directors 20 21 - Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to announce the appointment of Dr. Mary Lynne Hedley as a new member of its Board of Directors, effective April 28, 2021. Dr. Hedley is an immunologist and cancer cell biologist, with a vast level of experience within the pharmaceutical industry, specifically within the field of oncology. Most recently, Dr Hedley was Director, President and Chief Operating Officer at TESARO, a biotechnology company she co-founded in 2010, focused on the development and global commercialization of oncology therapeutics. During her time at TESARO the team built up a pipeline of early and late stage drug candidates including the commercial product niraparib, a PARP inhibitor that changed the treatment paradigm for women diagnosed with ovarian cancer. The company was acquired by GlaxoSm ....